Department of Otolaryngology, Massachusetts Eye & Ear, Boston, MA, U.S.A.
Department of Otolaryngology, Harvard Medical School, Boston, MA, U.S.A.
Laryngoscope. 2021 Oct;131(10):2169-2172. doi: 10.1002/lary.29454. Epub 2021 Feb 19.
OBJECTIVE/HYPOTHESIS: Determine contemporary incremental increases in healthcare expenditures and utilization associated with chronic rhinosinusitis (CRS).
Cross-sectional analysis of national health care survey data.
Patients reporting a diagnosis of CRS were extracted from the 2018 Medical Expenditure Panel Survey medical conditions file and linked to the consolidated expenditures file. CRS patients were then compared to non-CRS patients determining differences in healthcare utilization for office visits, emergency facility visits, and prescriptions filled as well as differences in total healthcare costs, office-based costs, prescription medication costs, and self-expenditures using demographically and comorbidity adjusted multivariate models. Results were compared to 2007, adjusted for inflation.
An estimated 7.28 ± 0.36 million adult patients reported CRS in 2018 (3.0 ± 0.1% of the adult U.S. population). The additional incremental healthcare utilizations associated with CRS relative to non-CRS patients for office visits, emergency facility visits, and number of prescriptions filled were 4.2 ± 0.6, 0.10 ± 0.03, and 6.0 ± 0.9, respectively (all P ≤ .003). Similarly, additional incremental healthcare expenditures associated with CRS for total health care expenses, office-based visit expenditures, prescription expenditures, and self-expenditures were $1,983 ± 569, $772 ± 139, $678 ± 213, and $68 ± 17, respectively (all P ≤ .002). Increases in total (+$1,062) and office based expenditures (+$360) compared to 2007 were significant.
CRS continues to be associated with a substantial incremental increase in healthcare utilization and expenditures. These expenditures have significantly outpaced inflation expected increases. The national healthcare costs of CRS have increased to an estimated $14.4 billion per year.
3 Laryngoscope, 131:2169-2172, 2021.
目的/假设：确定与慢性鼻-鼻窦炎（CRS）相关的当代医疗保健支出和利用的增量增加。
国家卫生保健调查数据的横断面分析。
从 2018 年医疗支出面板调查医疗条件文件中提取报告诊断为 CRS 的患者，并将其链接到合并支出文件。然后将 CRS 患者与非 CRS 患者进行比较，以确定门诊就诊、急诊就诊和处方用药的医疗保健利用差异，以及使用人口统计学和合并症调整后的多元模型确定总医疗保健费用、门诊费用、处方药物费用和自付费用的差异。结果与 2007 年进行了比较，并根据通货膨胀进行了调整。
据估计，2018 年有 728.0±0.36 万成年患者报告患有 CRS（占美国成年人口的 3.0±0.1%）。与非 CRS 患者相比，CRS 患者额外的医疗保健利用增量与门诊就诊、急诊就诊和处方用药数量分别为 4.2±0.6、0.10±0.03 和 6.0±0.9（均 P≤0.003）。同样，CRS 患者的总医疗保健费用、门诊就诊费用、处方支出和自付支出相关的额外增量医疗支出分别为 1983.0±569.0 美元、772.0±139.0 美元、678.0±213.0 美元和 68.0±17.0 美元（均 P≤0.002）。与 2007 年相比，总支出（增加 1062 美元）和门诊支出（增加 360 美元）均有显著增加。
CRS 继续与医疗保健利用和支出的大幅增量增加相关。这些支出的增长速度明显超过了预期的通胀增长。CRS 的国家医疗保健费用已增加到每年约 144 亿美元。
3 级喉镜，131：2169-2172，2021。
